KIT and neoplasm: Remarkably, PDGFRα and KIT are expressed at much higher levels in the normal kidney than in the tumor cells, showing that targeting of ccRCC by sunitinib is not as cancer-specific as desirable, which may explain observed sunitinib-induced toxicity.